GFG Capital’s AbbVie ABBV Stock Holding History

GFG Capital’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-81	Closed	-$15K	–	66
2025 Q2	$15K	Buy	+81	New	+$15.1K	﹤0.01%	174

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

GFG Capital's ABBV Position: Q3 2025 in Review

GFG Capital sold out of AbbVie (ABBV) in Q3 2025, closing a stake of 81 shares — an estimated $15K sold.

GFG Capital first reported a position in ABBV in Q2 2025 and held it in 1 quarter. The position peaked at $15K in Q2 2025. 3,906 funds tracked by Wall St. Rank hold ABBV as of Q3 2025.

GFG Capital reported no remaining AbbVie position as of Q3 2025 after selling out during the quarter.
GFG Capital sold 81 AbbVie shares in Q3 2025, an estimated $15K.
GFG Capital first reported a position in AbbVie in Q2 2025 and held it in 1 quarter.
GFG Capital's AbbVie position peaked at $15K in Q2 2025.
3,906 funds tracked by Wall St. Rank held AbbVie as of Q3 2025.

Based on GFG Capital's 13F filing for Q3 2025, filed 7 Oct 2025.